American Society of Clinical Oncology (ASCO) and Conexiant have launched ASCO AI in Oncology, a new online platform focused on artificial intelligence in cancer care. This platform helps cancer doctors and healthcare professionals learn how to use AI tools safely in treating patients and provide reliable information.
The American Society of Clinical Oncology (ASCO) and Conexiant had a partnership and launched two projects together. First is The ASCO Post, started in 2010, which became a trusted source for cancer news and expert opinions. Second is ASCO AI in Oncology, focus on artificial intelligence, which is one of the fastest-growing fields with advanced technology and modern medicine.
Artificial intelligence is already being used in cancer care today. AI tools are already in areas like medical imaging, pathology, risk assessment, and treatment planning. As there are multiple tools and claims available, it can be hard for doctors to know which ones are truly reliable and ready to use safely.
ASCO AI in Oncology doesn’t want to promote the AI trend, but to give doctors and healthcare teams the ability to deal with the fast growth of AI in cancer care, which can help doctors to get clarity and will be able to take precise decisions without delay. The platform acts as a learning space where oncology professionals need to stay updated with advanced tools and equipment.
AI shares trusted information from experts on clinical usefulness rather than technical discussion on how AI can help improve diagnosis, make tasks easier, and support more personalized treatment also shares expert advice that focuses on real-life patient care. It shows how AI can help doctors make better diagnoses, work more efficiently, and provide more personalized treatment.
ASCO CEO Clifford Hudis, MD said AI is growing fast, but there’s so much information that it can confuse doctors. This platform can be a problem-solver which precise, simple, practical way, helping doctors focus on what really matters: giving the best care to patients.
ASCO AI in Oncology shows that AI is not a miracle or something to fear, but a set of tools that need careful testing and smart use in real patient care.
Partnership with Conexiant, ASCO shows its goal of using AI responsibly to help cancer doctors and improve patient care with standard regulations.
ASCO, founded in 1964 and representing over 50,000 cancer doctors and researchers, aims to fight cancer through knowledge.
Now, that knowledge also means understanding AI tools, knowing their limits, and using them safely and responsibly to help patient.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
